Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Aranesp Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 19, 2008
Alimta (Lilly): YES!!!!
Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: GLG Expert Contributor
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
May 15, 2008
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: GLG Expert Contributor
"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."
May 13, 2008
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.
May 12, 2008
ImClone: Does Morgan Stanley (MS) know something we don't??
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: GLG Expert Contributor
Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...
May 7, 2008
Genomics are coming! Are we ready?
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: GLG Expert Contributor
Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind...
May 6, 2008
Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
May 6, 2008
Amplimed (?) anything for pancreatic ca would be worthwile.
Analysis of: AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
An interesting randomized phase II trial of Gemzar (the current standard with Tarceva) vs imexon + Gemzar. BUT shouldn't it be compared to Gemzar/ Tarceva??
May 5, 2008
Ricin Vaccine Market Relies on Threat of Terror
Analysis of: DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVaxTM, Its Vaccine Against Ricin Toxin | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Ricin is an extraordinarily potent toxin that is fatal because of its ability to inhibit protein synthesis and rapidly cause multisystem failure.  Because ricin can be prepared from castro beans, it has the potential to be used in terrorist attacks.  The present vaccine has the potential to...
May 5, 2008
Too Early to Draw Conclusions Yet on Vargatef
Analysis of: Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Vargatef is a novel angiokinase inhibitor that blocks VEGF, PDGR and FGF receptors.  The current phase II study in patients with non small cell lung cancer shows that this oral agent can be given safely.  It is far too early to draw conclusions regarding efficacy.
May 5, 2008
AstraZeneca's (AZ) IRESSA still alive in Europe.....? There is life after failure in the US.
Analysis of: AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA(TM)) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Approval will be base on the phase III INTEREST trial that showed in NSCLC that Iressa was "non-inferior" to standard chemotherapy after platinum therapy failure first line. Iressa was better tolerated and had an improved quality of life.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 582

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637